VYLUMA ANNOUNCES POSITIVE RESULTS FROM SECOND STAGE OF PHASE III CHAMP STUDY OF NVK002 FOR THE TREATMENT OF MYOPIA IN CHILDREN
Vyluma announced today positive top-line results from the second stage of its Phase III CHAMP (Childhood Atropine for Myopia Progression) clinical study of its lead compound…
